Astellas Pharma Inc. (TYO:4503)

Astellas Pharma Cash Flow Statement

Financials in millions JPY. Fiscal year is April - March.

Operating Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Net Income	385,577	376,587	31,237	24,969	132,361	156,886
Depreciation & Amortization	198,812	194,594	199,132	157,840	105,738	79,684
Loss (Gain) From Sale of Assets	-	54,187	187,564	78,931	84,499	74,850
Other Operating Activities	17,418	-92,565	-75,674	-37,563	-68,811	-43,293
Change in Accounts Receivable	-78,681	-63,794	-104,735	-55,948	-4,849	-8,001
Change in Inventory	-5,595	-16,218	-50,225	-60,036	-7,086	24,058
Change in Accounts Payable	-2,810	-307	-11,409	29,466	-12,274	-10,101
Change in Other Net Operating Assets	-34,635	107,704	18,622	34,816	98,189	-16,639
Operating Cash Flow	547,645	560,188	194,512	172,475	327,767	257,444
Operating Cash Flow Growth	37.01%	188.00%	12.78%	-47.38%	27.32%	-16.10%

Investing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Capital Expenditures	-56,180	-57,723	-37,003	-38,056	-36,441	-30,739
Sale of Property, Plant & Equipment	-	-	-	-	-	441
Cash Acquisitions	-	-	-	-784,974	-	-670
Sale (Purchase) of Intangibles	-54,777	-26,922	-19,168	-33,438	-51,888	-21,428
Investment in Securities	-12,243	-	12,920	-	12,624	-
Other Investing Activities	4,812	17,923	-46,168	10,666	-8,795	-10,017
Investing Cash Flow	-118,388	-66,722	-89,419	-845,802	-84,500	-62,413

Financing Activities

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Short-Term Debt Issued	-	-	-	324,337	-	-
Long-Term Debt Issued	-	-	200,000	472,275	50,000	-
Total Debt Issued	154,697	-	200,000	796,612	50,000	-
Short-Term Debt Repaid	-	-185,625	-236,449	-	-15,000	-
Long-Term Debt Repaid	-	-81,793	-52,073	-25,379	-50,000	-60,000
Total Debt Repaid	-488,987	-267,418	-288,522	-25,379	-65,000	-60,000
Net Debt Issued (Repaid)	-334,290	-267,418	-88,522	771,233	-15,000	-60,000
Repurchase of Common Stock	-598	-730	-6,960	-10,735	-60,556	-50,717
Common Dividends Paid	-139,726	-136,099	-128,993	-116,653	-100,355	-85,236
Other Financing Activities	-4,820	-532	-36,892	-29,785	-19,712	-20,345
Financing Cash Flow	-479,434	-404,779	-261,367	614,060	-195,623	-216,298

Net Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Foreign Exchange Rate Adjustments	1,351	4,547	8,960	18,113	13,210	11,125
Miscellaneous Cash Flow Adjustments	-1	-	-1	1	-	-1
Net Cash Flow	-48,827	93,234	-147,315	-41,153	60,854	-10,143

Free Cash Flow

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Free Cash Flow	491,465	502,465	157,509	134,419	291,326	226,705
Free Cash Flow Growth	34.26%	219.01%	17.18%	-53.86%	28.50%	-17.70%
Free Cash Flow Margin	20.65%	23.49%	8.24%	8.38%	19.18%	17.49%
Free Cash Flow Per Share	273.43	279.60	87.64	74.69	159.63	122.50
Levered Free Cash Flow	308,833	426,793	125,260	134,671	202,242	174,913
Unlevered Free Cash Flow	316,606	433,246	133,980	139,311	204,253	176,360

Additional Metrics

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Sep 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash Income Tax Paid	136,745	98,612	85,478	38,112	69,479	42,093
Change in Working Capital	-121,721	27,385	-147,747	-51,702	73,980	-10,683

Data Source: S&P Global Market Intelligence Last updated: Nov 4, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 6, 2026

Data Sources Report a data error